

Definitive amount of capital increase and Communication regarding the details of stabilisation operations

The Lead Manager and Bookrunner of the issue by STENTYS (the Company) of new shares on the occasion of its admission for trading on the regulated market of NYSE Euronext Paris has informed the company that it has not exercised the over-allotment option granted to it. As a result the definitive amount of the capital increase is approximately €22.7 million, corresponding to the issue of 1,893,939 new shares.

In addition, in accordance with article 631-10 of the General Regulations of the AMF (French financial market authorities), Société Générale, acting as stabilisation agent on behalf of the underwriters, has indicated that:

- it has engaged in stabilisation operations for STENTYS shares (ISIN code: FR0010949404);
- these operations began on 25 October 2010;
- the last stabilisation operation was conducted on 18 November 2010;
- stabilisation operations were carried out at the following prices:

Date	Lowest price	Highest price
25/10/10	11.93	12
26/10/10	11.92	12
27/10/10	11.87	12
29/10/10	11.15	12
01/11/10	11.97	12
02/11/10	12	12
03/11/10	11.95	12
04/11/10	11.95	12
05/11/10	12	12
08/11/10	11.83	12
11/11/10	11.6	11.85
12/11/10	11.65	11.65
15/11/10	11.24	11.43
16/11/10	10.1	10.74
18/11/10	10	10

The partners in the operation were:



Lead Manager and Bookrunner



Member of placement syndicate

PiperJaffray

Co-Lead Manager

Allegra Finance

Counsel for Stentys

Public information

The legal and financial documents required to be made available to shareholders may be consulted at the registered office of the Company, 25 rue de Choiseul, 75002 Paris.

Copies of the Prospectus filed by the Autorité des marchés financiers on October 12th, 2010 under the number 10-362 are available free of charge from the Company and from the Lead Underwriter and the Co-underwriter. The Prospectus may be viewed on the websites of the Company (www.stentys.com) and of the AMF (www.amf-france.org).

The attention of investors is drawn to Section 4 "Risk Factors" of the "Document de Base" registered with the AMF and to Section 2 "Risk Factors" contained in the "Note d'opération", and, in particular, to the specific risks related to the two Company's licensing agreements.

About STENTYS:

Based in Paris (France) and Princeton, N.J. (USA), the STENTYS Company has developed a new generation of stents to treat acute myocardial infarction. Founded by Jacques Séguin, Professor of Cardiac Surgery, and Gonzague Issenmann, STENTYS received the CE mark for its flagship products in 2010. Its self-apposing stents adapt the anatomic changes of the arteries in the post-infarction phase and prevents conventional stents mal-apposition problems. STENTYS has started its marketing activities in several European countries.

More information on www.stentys.com

Stentys

Stanislas Piot
Directeur financier
Tel.: +33 (0)1 44 53 99 42
investors@stentys.com

NewCap.

Communication financière, Relations Investisseurs et Presse
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
stentys@newcap.fr

STENTYS is listed on NYSE Euronext Paris
ISIN : FR0010949404 – STNT

DISCLAIMER

This press release does not constitute an offer to sell, or a solicitation of an offer to buy STENTYS shares. If you wish to obtain further information about STENTYS, please refer to our website www.stentys.com. This press release may contain some forward-looking statements. Although STENTYS considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements. STENTYS operates in a continually changing environment and new risks emerge continually. STENTYS does not undertake and expressly disclaims any obligation to update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act